Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a report released on Sunday morning. The brokerage issued a hold rating on the medical research company's stock.

CTSO has been the topic of several other reports. HC Wainwright reiterated a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reiterated a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Cytosorbents presently has a consensus rating of "Moderate Buy" and a consensus target price of $4.67.

Cytosorbents Price Performance

CTSO stock traded up $0.14 during trading on Friday, hitting $1.14. The company had a trading volume of 188,711 shares, compared to its average volume of 314,488. The firm has a market capitalization of $62.34 million, a price-to-earnings ratio of -3.17 and a beta of 0.61. The business has a 50 day moving average of $1.04 and a 200 day moving average of $1.05. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Remove Ads

Institutional Trading of Cytosorbents

Several institutional investors and hedge funds have recently bought and sold shares of CTSO. Sargent Investment Group LLC raised its holdings in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock worth $2,439,000 after buying an additional 192,747 shares during the period. Avenir Corp raised its holdings in Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after buying an additional 118,387 shares during the period. Raymond James Financial Inc. acquired a new stake in Cytosorbents during the 4th quarter worth about $99,000. Millennium Management LLC acquired a new position in shares of Cytosorbents in the 4th quarter valued at about $30,000. Finally, Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.